Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
How UPMC Enterprises changes the game for health care start-ups
Tal Heppenstall, the president of UPMC Enterprises, said fear of failure holds back many of the health systems that are jumping into the digital health startup and investment arena.
Via Oncology Acquired by Elsevier
As announced Jan. 17, Elsevier, which publishes more than 2,500 digital journals, including Lancet and …
UPMC Enterprises at HIMSS 2018
Who is speaking? We are excited to announce Dr. Rasu Shrestha, Chief Innovation Officer, UPMC, and Executive Vice President, UPMC Enterprises, and Dr. Pamela Peele, Chief Analytics Officer,